AXLRx Book a callCommission
Twenty minutes with a consultant, before anything is commissioned.Book a scoping call →

About AXLRx

A commercial consulting engine for pharma.

A launch team needs the competitive map before it can plan. An access team needs the payer logic before it can build the case. Neither has six weeks to wait for it. AXLRx is a custom-built commercial consulting engine that delivers evidence-led answers to the questions that move your decision — competitive, patient and payer intelligence, scoped to your asset, in 72 hours. A syndicated report describes the market. An AXLRx brief frames the decision your launch and access teams have to make.

It is a service, not a subscription. There is no platform to operate, no seat licence and no dashboard to learn. You bring the question in front of you, and we return a PDF brief, an Excel model and a PowerPoint readout. Every figure is verified against a live source. If it cannot be sourced, it does not ship.

The method

How we research

Three disciplines, one standard: verify or drop.

01Source ingestionLive connectors to the primary record: regulatory, clinical, epidemiological, financial and payer sources. No secondary summaries.
02VerificationEvery claim is cited to a live PMID, trial ID or URL at the point of writing, numerically cross-checked, then re-checked in an independent audit pass. Model memory is never a source.
03DeliveryA decision-structured PDF, an editable Excel model and a PowerPoint readout. Every brief includes an analyst review and a 45-minute call.
FDAPubMedClinicalTrials.govEMANICESEC / EDGARWHOSFDACMSopenFDA
319analyses published
21indications
22live connectors
20+years of pharma practice
72hquestion to deliverable

How we research

Three disciplines, one standard: verify or drop.

Source ingestionLive connectors to the primary record: regulatory, clinical, epidemiological, financial and payer sources. No secondary summaries.
VerificationEvery claim is cited to a live PMID, trial ID or URL at the point of writing, numerically cross-checked, then re-checked in an independent audit pass. Model memory is never a source.
DeliveryA decision-structured PDF, an editable Excel model and a PowerPoint readout. Every brief includes an analyst review and a 45-minute call.
A service, not a subscriptionThere is no platform to operate, no seat licence and no dashboard to learn.

The team

The team

Built by pharma strategy veterans, not generalist AI engineers. Every brief is reviewed by an experienced commercial consultant before it reaches you.

Naresh Gupta
Founder

Naresh Gupta

Founder & Director · IIM Ahmedabad · Ex-ZS Associates · Ex-Novartis · 20+ years

Pharma commercial operations across GCC, South Asia, and Europe — field sales, business development, field force strategy, and commercial program leadership. Specialisation in rare disease, specialty, and market access.

NGNaresh GuptaFounder & Director · IIM Ahmedabad · Ex-ZS Associates · Ex-Novartis · 20+ years

Pharma commercial operations across GCC, South Asia and Europe — field sales, business development, field force strategy, analytics and commercial program leadership. Specialisation in rare disease, specialty and market access.

AAnalyst BenchCommercial Analysts · Deep commercial analytics experience

Commercial analysts who author and review every brief against the verify-or-drop standard.

RxAdvisory BoardTherapy-area advisors · KOL & ex-payer

Clinical and ex-payer advisors who pressure-test the commercial read for each therapy area before delivery.

“The difference between a good strategy and a winning one is not the strategy. It is the operational discipline around it.”

Naresh Gupta · Founder, MoatRx

Commission your first brief.

Scope confirmed in 24 hours. Delivered in 72.